Analysis of Anti-tumor Targeted Drugs Induced Lung Disease
SUN Xue-lin, ZHU Yi, FENG Yu-fei, HU Xin
Author information+
Department of Pharmacy, National Center of Gerontology, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Beijing Hospital, Beijing 100730, China;
OBJECTIVE To analyze the types of lung injury caused by targeted anti-tumor post-market drugs in China, and provide guidance for clinical safety administration. METHODS we sorted out the targeted anti-tumor drugs on the market in China by searching the CFDA website, listed the mechanism of action drugs and time on the market. To list the types of drug induced lung injury, we searched the pubmed, China knowledge net database, wangfang database, VIP database and drug instructions. RESULTS Targeted anti-tumor drugs came into China since 2000. There are 26 kinds of anti-tumor drugs, covering 8 malignant tumors. Targeted anti-tumor drug-related lung injury was noted in 24 drug package inserts. Literature search results showed that 19 kinds of targeted anti-tumor drugs could cause lung injury in different degrees, and the types of lung injury were more than those were listed in package inserts. CONCLUSION Lung injury is one of the common adverse effect of targeted anti-tumor drugs, most of targeted anti-tumor drugs have pulmonary toxicity. Clinical management and monitoring should be strengthened to promote rational clinical safe drug use.
[1] TAYLOR A C, VERMA N, SLATER R, et al. Bad for breathing:a pictorial of drug-induced pulmonary disease[J]. Curr Probl Diagn Radiol, 2016, 45(6):429-432. [2] LUO C, LV M, LI Y, et al. Gefitinib-induced interstitial pneumonia: a case report and review of the literature[J]. Exp Ther Med, 2014, 7(4):855-859. [3] KUO L C, LIN P C, WANG K F, et al. Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid:a case report and literature review[J]. Med Oncol, 2011, 28(1):79-82. [4] GAO B A, ZHANG L Y, CHEN S X, et al. Two cases of interstitial lung disease caused by gefitinib and literature review[J]. Chin J Respir Crit Care Med(中国呼吸与危重监护杂志), 2013, 12(5):513-515. [5] SAJIDA Y, KITASATO Y, KAWANO Y, et al. A case of alveolar hemorrhage caused by gefitinib[J]. J Japan Respir Soc, 2011, 49(7):506-510. [6] NAGARIA N C, COGSWELL J, CHOE J K, et al. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis[J]. J Clin Oncol, 2005, 23(10):2423-2424. [7] PENG W, GAO J, MOU L Y. Death from pulmonary interstitial and liver damage after taking gefitinib[J]. Adv Drug React J(药物不良反应杂志), 2009,11(6):429-430. [8] NI L F, LIU X M, GAO L. Gefitinib-induced acute lung injury: a case report and review of the literature[J]. Chin J Lung Cancer(中国肺癌杂志), 2011, 14(2):173-176. [9] ZONG X F, XIE L Y, LU J, et al. Clinical analysis of erlotinib-induced severe rash and fatal interstitial lung disease: a case report and literature review[J]. Chin J Respir Crit Care Med(中国呼吸与危重监护杂志), 2014,13(3):273-276. [10] LEI L, LUO J Z, MENG J Y, et al. Death from acute interstitial lung disease related to erlotinib:2 case reports[J]. Adv Drug React J(药物不良反应杂志), 2007,9(4):277-278. [11] UM S J, LEE S K, YANG D K, et al. Fatal interstitial lung disease after erlotinib administration in a patient with radiation fibrosis[J]. Clin Respir J, 2009,3(3):181-184. [12] LAI Y C, LIN P C, LAI J I, et al. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid:a case report and literature review[J]. Int J Clin Pharmacol Ther, 2011,49(7):461-466. [13] ZHANG J, ZHAN Y, OUYANG M, et al. Fatal interstitial lung disease associated with icotinib[J]. J Thor Dis, 2014, 6(12):267-271. [14] DAI Y H, WANG J H, FU Q, et al. The efficacy and toxicity of icotinib in the treatment for 190 cases with advanced NSCLC[J]. China Cancer(中国肿瘤), 2015, 24(2):149-154. [15] TANI T, NAOKI K, ASAKURA T, et al. Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib-and erlotinib-induced interstitial lung disease:a case report[J]. Mol Clin Oncol, 2016, 5(4):488-490. [16] TAKAKUWA O, OGURI T, UEMURA T, et al. Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: a case report[J]. Mol Clin Oncol, 2017,7(3):383-385. [17] TACHI H, SHIOZAWA T, SAKAI C, et al. Osimertinib-induced interstitial lung disease presenting as eosinophilic pneumonia[J]. J Thor Oncol, 2017,12(8):118-120. [18] ONO A, TAKAHASHI T, OISHI T, et al. Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib[J]. J Clin Oncol, 2013,31(26):417-419. [19] SHASH H, STEFANOVICI C, PHILLIPS S, et al. Aggressive metastatic inflammatory myofibroblastic tumor after allogeneic stem cell transplant with fatal pulmonary toxicity from crizotinib[J]. J Pediatr Hematol Oncol, 2016,38(8):642-645. [20] SEKIMOTO Y, KATO M, SHUKUYA T, et al. Bevacizumab-induced chronic interstitial pneumonia during maintenance therapy in non-small cell lung cancer[J]. Respirol Case Rep, 2016,4(2):e00151. [21] PRASANNA T, BRIGGS G, JAIN S, et al. Massive fatal pulmonary haemorrhage during bevacizumab treatment following microwave ablation therapy for oligometastatic lung metastasis from rectal cancer[J]. Interact Cardiov Thor Surg, 2017, 26(3):514-515. [22] TOGASHI Y, KIM Y H, MASAGO K, et al. Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab[J]. Int J Clin Oncol, 2011,16(4):444-446. [23] SUGAYA A, ISHIGURO S, MITSUHASHI S, et al. Interstitial lung disease associated with trastuzumabmonotherapy: a report of 3 cases[J]. Mol Clin Oncol, 2017, 6(2):229-232. [24] VAHID B, MEHROTRA A. Trastuzumab (herceptin)-associated lung injury[J]. Respirology, 2006, 11(5):655-658. [25] BETTINI A C, TONDINI C, POLETTI P, et al. A case of interstitial pneumonitis associated with Guillain-Barré syndrome during administration of adjuvant trastuzumab[J]. Tumori, 2008, 94(5):737-741. [26] LIU X L, FU Y L, ZHU Q Y, et al. Analysis of adverse reaction caused by trastuzumab[J]. Pharm Clin Res(药学与临床研究), 2017, 25(1):63-66. [27] YAMAMOTO D, YAMAMOTO C, YAMAMOTO M. A case of interstitial pneumonitis induced by lapatinib plus letrozole[J]. Cancer Chemothr, 2016, 43(12):2059-2061. [28] CAPRI G, CHANG J, CHEN S C, et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer[J]. Ann Oncol, 2010, 21(3):474-480. [29] TAKEDA H, NISHIKAWA H, IGUCHI E, et al. Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma:report of three cases[J]. Clin J Gastroenterol, 2012, 5(4):407-412. [30] SHUTO T, MURAKAMI M, SHIMIZU J, et al. Treatment experience with sorafenib for lung metastases of hepatocellular carcinoma complicated with interstitial pneumonia[J]. Cancer Chemother, 2016, 43(12):1582-1584. [31] DE WULF S, COULIER B, REZAZADEH A A, et al. CT halo sign and crazy paving pattern due to lung metastases hemorrhage after sunitinib therapy[J]. Diagn Interv Imaging, 2017, 98(1):93-95. [32] KUSHIMA H, ISHII H, KADOTA J. Sunitinib-related interstitial pneumonia after treatment with temsirolimus:a case of possible recall phenomenon[J]. Int J Urol, 2014, 21(4):420-421. [33] SEKIGUCHI Z, TAKIZAWA A, TAKESHIMA T, et al. A case of interstitial lung disease due to sunitinib[J]. Hinyokika Kiyo, 2012,58(9):481-485. [34] IDE S, SAKAMOTO N, HARA S, et al. Interstitial lung disease induced by pazopanib treatment[J]. Intern Med, 2017,56(1):79-83. [35] CARBONNAUX M, MOLIN Y, SOUQUET P J, et al. Pneumocystis jirovecii pneumonia under everolimus in two patients with metastatic pancreatic neuroendocrine tumors[J]. Invest New Drugs, 2014, 32(6):1308-1310. [36] SIDDIQUI A S, ZIMMERMAN J L. Everolimus associated interstitial pneumonitis in a liver transplant patient[J]. Respir Med Case Rep, 2016, 19:15-17. [37] KUROKAWA M, NAITO S, ICHIYANAGI O, et al. Spontaneous remission of everolimus-induced interstitial lung disease in metastatic renal cell carcinoma:an autopsy case report[J]. Hinyokika Kiyo, 2017, 63(9):377-380. [38] MALOUF M A, HOPKINS P, SNELL G, et al. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis[J]. Respirology,2011,16(5):776-783. [39] CAO L, CHEN J Y. Noninfectious pneumonitis caused by everolimus therapy for recurrent breast cancer:a case report[J]. Chin J New Drugs(中国新药杂志), 2014, 23(24):2938-2942. [40] WANG Y H, ZHAO J, WANG L R, et al. Acute lung injury after bortezomib treatment for multiple myeloma:a case report and literature review[J]. Chin J Clinicians(中华临床医师杂志), 2013, 7(19):8987-8988. [41] SOCOLA F, LOAIZA-BONILLA A, BENEDETTO P. Axitinib induced recurrent pneumothorax following near-complete response of renal cell carcinoma lung metastasis:an unexpected complication[J]. Case Rep Oncol Med, 2012, 2012:390702. [42] GAO Y, GAO Y L, YU S H, et al. Clinical analysis of lung injury induced by rituximab[J]. Chin J Coal Ind Med(中国煤炭工业医学杂志), 2017, 20(3):294-296. [43] KHAN B A, KHAN S, WHITE B, et al. Severe pneumocystis jiroveci pneumonia in a patient on temozolomide therapy: a case report and review of literature[J]. Respir Med Case Rep, 2017, 22(C):179-182. [44] YOKOYAMA T, MIYAZAWA K, KURAKAWA E, et al. Interstitial pneumonia induced by imatinib mesylate:pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration[J]. Leukemia, 2004,18(3):645-646. [45] LIN J T, YEH K T, FANG H Y, et al. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate[J]. Leuk Lymphoma, 2006, 47(8):1693-1695. [46] SEKI N, ITO A, WATANABE K, et al. Irreversible imatinib-induced pneumonitis following long-term imatinib administration[J]. Intern Med, 2007, 46(23):1941-1942. [47] MU W J, REN X L, ZHANG L, et al. A case of drug-related lung damages induced by imatinibmesylate[J]. Drug Eval(药品评价), 2015,12(4):40-42. [48] GO S I, LEE W S, LEE G W, et al. Nilotinib-induced interstitial lung disease[J]. Int J Hematol, 2013, 98(3):361-365. [49] RIOU M, SEFERIAN A, SAVALE L, et al. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity[J]. Eur Respir J, 2016,48(5):1517-1519. [50] RADAELLI F, BRAMANTI S, FANTINI N N, et al. Dasatinib-related alveolar pneumonia responsive to corticosteroids[J]. Leuk Lymphoma, 2006, 47(6):1180-1181. [51] SHINOHARA A, KOGO R, URYU H, et al. A case of pneumocystis pneumonia after cetuximab-based bioradiotherapy[J]. Nihon Jibiinkoka Gakkai Kaiho,2016,119(3):204-209. [52] XU M, HUANG H, XIONG Y, et al. Combined chemotherapy plus endostar with sequential stereotactic radiotherapy as salvage treatment for recurrent esophageal cancer with severe dyspnea:a case report and review of the literature[J]. Oncol Lett, 2014, 8(1):291-294. [53] HU B, CHEN G L, WANG H. Research progress of nebulized heparin for acute lung injury[J]. Chin Pharm J(中国药学杂志), 2017, 52(4):258-262.